Independent analysis puts a Homopeptide semaglutide lot at 96.0%, against 92.4% on the certificate
The result is unremarkable. What the report omits is not.
Coverage naming Homopeptide
Reporting from across the Journal that names Hunan Aslsen Technology Co., Ltd., or that bears directly on the questions its dossier leaves open. The dossier itself — the testing record, the correspondence log and the verification box — is here.
Independent analysis puts a Homopeptide retatrutide lot at 98.3%, against 97.3% on the certificate
The result is unremarkable. What the report omits is not.
Independent analysis puts a Homopeptide semaglutide lot at 98.1%, against 95.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
What changed at Homopeptide in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at Homopeptide in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Homopeptide declines, for the 4th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Homopeptide declines, for the 20th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Homopeptide declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Homopeptide declines, for the 9th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Homopeptide declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at Homopeptide in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a Homopeptide retatrutide lot at 98.9%, against 98.1% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a Homopeptide mazdutide lot at 99.2%, against 98.5% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Homopeptide declines, for the 12th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a Homopeptide tirzepatide lot at 99.3%, against 95.3% on the certificate
The result is unremarkable. What the report omits is not.
Homopeptide declines, for the 8th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a Homopeptide orforglipron lot at 99.1%, against 98.4% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Homopeptide declines, for the 17th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a Homopeptide cagrilintide lot at 98.1%, against 94.7% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Homopeptide declines, for the 21st time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.